[Form 4] Alignment Healthcare, Inc. Insider Trading Activity
Alignment Healthcare Chief Medical Officer Hyong (Ken) Kim reported the sale of 18,600 shares of the company’s common stock on 08/13/2025 under a Rule 10b5-1 trading plan adopted on 03/14/2025. The sales generated a weighted-average price of $15.0327 per share, with individual trades executed between $15.00 and $15.09. After the reported transactions, the reporting person beneficially owned 472,167 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses the plan adoption date and the price range for the multiple sales.
Hyong (Ken) Kim, Chief Medical Officer di Alignment Healthcare, ha comunicato la vendita di 18.600 azioni ordinarie della società il 13/08/2025, nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 14/03/2025. Le vendite hanno prodotto un prezzo medio ponderato di 15,0327 USD per azione, con singole operazioni eseguite tra 15,00 e 15,09 USD. Dopo le operazioni riportate, la persona interessata deteneva beneficiariamente 472.167 azioni. Il Modulo 4 è stato firmato da un procuratore per conto della persona che ha presentato la dichiarazione e indica la data di adozione del piano e l'intervallo di prezzo delle vendite multiple.
Hyong (Ken) Kim, Director Médico de Alignment Healthcare, informó la venta de 18.600 acciones ordinarias de la compañía el 13/08/2025 bajo un plan de negociación Rule 10b5-1 adoptado el 14/03/2025. Las ventas generaron un precio medio ponderado de 15,0327 USD por acción, con operaciones individuales ejecutadas entre 15,00 y 15,09 USD. Tras las transacciones notificadas, la persona informante poseía de manera beneficiaria 472.167 acciones. El Formulario 4 fue firmado por un apoderado en nombre del informante y revela la fecha de adopción del plan y el rango de precios de las ventas múltiples.
Alignment Healthcare의 최고의료책임자(Chief Medical Officer) Hyong(겐) Kim은 2025-08-13에 회사 보통주 18,600주를 Rule 10b5-1 거래계획에 따라 매각했다고 보고했습니다. 해당 계획은 2025-03-14에 채택되었습니다. 매각으로 주당 가중평균 가격은 15.0327달러가 되었고, 개별 거래는 15.00달러에서 15.09달러 사이에서 이루어졌습니다. 보고된 거래 이후 보고인은 실질적으로 472,167주를 보유하고 있었습니다. Form 4는 보고인을 대신한 대리인이 서명했으며, 계획 채택일과 다건 매각의 가격 범위를 공개하고 있습니다.
Hyong (Ken) Kim, Chief Medical Officer d'Alignment Healthcare, a déclaré la vente de 18 600 actions ordinaires de la société le 13/08/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 14/03/2025. Les ventes ont généré un prix moyen pondéré de 15,0327 USD par action, avec des transactions individuelles exécutées entre 15,00 et 15,09 USD. Après les opérations signalées, la personne déclarante détenait bénéficiairement 472 167 actions. Le formulaire 4 a été signé par un mandataire pour le compte de la personne déclarante et indique la date d'adoption du plan ainsi que la fourchette de prix des ventes multiples.
Hyong (Ken) Kim, Chief Medical Officer von Alignment Healthcare, meldete den Verkauf von 18.600 Stammaktien des Unternehmens am 13.08.2025 im Rahmen eines am 14.03.2025 eingeführten Rule-10b5-1-Handelsplans. Die Verkäufe ergaben einen gewogenen Durchschnittspreis von 15,0327 USD je Aktie; einzelne Transaktionen lagen zwischen 15,00 und 15,09 USD. Nach den gemeldeten Transaktionen hielt die meldepflichtige Person wirtschaftlich 472.167 Aktien. Das Formular 4 wurde von einem Bevollmächtigten im Namen der meldepflichtigen Person unterzeichnet und gibt das Einführungsdatum des Plans sowie die Preisspanne der mehreren Verkäufe an.
- Transaction executed under a Rule 10b5-1 plan adopted 03/14/2025, indicating pre-authorized trades
- Disclosure of weighted-average price and per-share price range ($15.00 to $15.09) with an offer to provide detailed breakdown on request
- Disposition of 18,600 shares on 08/13/2025 reduced the reporting person’s holdings
- Beneficial ownership decreased to 472,167 shares following the reported sale
Insights
TL;DR: Insider sold a small portion of holdings under a pre-established 10b5-1 plan; disclosure is routine and non-material on its face.
The Form 4 shows a planned disposition of 18,600 shares executed on 08/13/2025 under a Rule 10b5-1 plan adopted 03/14/2025. The use of a 10b5-1 plan indicates trades were pre-authorized; the filing reports a weighted-average sale price of $15.0327 and a disclosed per-share price range of $15.00 to $15.09. Post-transaction beneficial ownership stands at 472,167 shares. For most investors this is a routine insider liquidity event rather than a corporate-change signal.
TL;DR: Disclosure meets Section 16 requirements and documents a Rule 10b5-1 plan sale with transparent price-range reporting.
The filing clearly identifies the reporting person’s role as Chief Medical Officer and confirms the transaction was executed pursuant to a 10b5-1 plan adopted 03/14/2025. The reporting includes a weighted-average sale price and a commitment to provide transaction-level pricing if requested, which enhances transparency. The filing is signed by an attorney-in-fact, consistent with permitted representation on Form 4 submissions.
Hyong (Ken) Kim, Chief Medical Officer di Alignment Healthcare, ha comunicato la vendita di 18.600 azioni ordinarie della società il 13/08/2025, nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 14/03/2025. Le vendite hanno prodotto un prezzo medio ponderato di 15,0327 USD per azione, con singole operazioni eseguite tra 15,00 e 15,09 USD. Dopo le operazioni riportate, la persona interessata deteneva beneficiariamente 472.167 azioni. Il Modulo 4 è stato firmato da un procuratore per conto della persona che ha presentato la dichiarazione e indica la data di adozione del piano e l'intervallo di prezzo delle vendite multiple.
Hyong (Ken) Kim, Director Médico de Alignment Healthcare, informó la venta de 18.600 acciones ordinarias de la compañía el 13/08/2025 bajo un plan de negociación Rule 10b5-1 adoptado el 14/03/2025. Las ventas generaron un precio medio ponderado de 15,0327 USD por acción, con operaciones individuales ejecutadas entre 15,00 y 15,09 USD. Tras las transacciones notificadas, la persona informante poseía de manera beneficiaria 472.167 acciones. El Formulario 4 fue firmado por un apoderado en nombre del informante y revela la fecha de adopción del plan y el rango de precios de las ventas múltiples.
Alignment Healthcare의 최고의료책임자(Chief Medical Officer) Hyong(겐) Kim은 2025-08-13에 회사 보통주 18,600주를 Rule 10b5-1 거래계획에 따라 매각했다고 보고했습니다. 해당 계획은 2025-03-14에 채택되었습니다. 매각으로 주당 가중평균 가격은 15.0327달러가 되었고, 개별 거래는 15.00달러에서 15.09달러 사이에서 이루어졌습니다. 보고된 거래 이후 보고인은 실질적으로 472,167주를 보유하고 있었습니다. Form 4는 보고인을 대신한 대리인이 서명했으며, 계획 채택일과 다건 매각의 가격 범위를 공개하고 있습니다.
Hyong (Ken) Kim, Chief Medical Officer d'Alignment Healthcare, a déclaré la vente de 18 600 actions ordinaires de la société le 13/08/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 14/03/2025. Les ventes ont généré un prix moyen pondéré de 15,0327 USD par action, avec des transactions individuelles exécutées entre 15,00 et 15,09 USD. Après les opérations signalées, la personne déclarante détenait bénéficiairement 472 167 actions. Le formulaire 4 a été signé par un mandataire pour le compte de la personne déclarante et indique la date d'adoption du plan ainsi que la fourchette de prix des ventes multiples.
Hyong (Ken) Kim, Chief Medical Officer von Alignment Healthcare, meldete den Verkauf von 18.600 Stammaktien des Unternehmens am 13.08.2025 im Rahmen eines am 14.03.2025 eingeführten Rule-10b5-1-Handelsplans. Die Verkäufe ergaben einen gewogenen Durchschnittspreis von 15,0327 USD je Aktie; einzelne Transaktionen lagen zwischen 15,00 und 15,09 USD. Nach den gemeldeten Transaktionen hielt die meldepflichtige Person wirtschaftlich 472.167 Aktien. Das Formular 4 wurde von einem Bevollmächtigten im Namen der meldepflichtigen Person unterzeichnet und gibt das Einführungsdatum des Plans sowie die Preisspanne der mehreren Verkäufe an.